vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and ORRSTOWN FINANCIAL SERVICES INC (ORRF). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $64.6M, roughly 1.2× ORRSTOWN FINANCIAL SERVICES INC). ORRSTOWN FINANCIAL SERVICES INC runs the higher net margin — 33.8% vs -9.6%, a 43.4% gap on every dollar of revenue. Over the past eight quarters, ORRSTOWN FINANCIAL SERVICES INC's revenue compounded faster (39.3% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Orrstown Financial Services Inc is a US regional bank holding company headquartered in Shippensburg, Pennsylvania. It offers a full range of retail and commercial banking solutions including deposit accounts, personal and business loans, mortgages, and wealth management services, primarily serving customers across central Pennsylvania and northern Maryland.

BIOX vs ORRF — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.2× larger
BIOX
$77.6M
$64.6M
ORRF
Higher net margin
ORRF
ORRF
43.4% more per $
ORRF
33.8%
-9.6%
BIOX
Faster 2-yr revenue CAGR
ORRF
ORRF
Annualised
ORRF
39.3%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
ORRF
ORRF
Revenue
$77.6M
$64.6M
Net Profit
$-7.4M
$21.8M
Gross Margin
46.8%
Operating Margin
9.3%
Net Margin
-9.6%
33.8%
Revenue YoY
-16.8%
Net Profit YoY
-20.2%
19.1%
EPS (diluted)
$-0.12
$1.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
ORRF
ORRF
Q1 26
$64.6M
Q4 25
$64.9M
Q3 25
$77.6M
$64.4M
Q2 25
$62.4M
Q1 25
$60.6M
$60.4M
Q4 24
$98.8M
$61.8M
Q3 24
$93.3M
$64.1M
Q2 24
$33.3M
Net Profit
BIOX
BIOX
ORRF
ORRF
Q1 26
$21.8M
Q4 25
$21.5M
Q3 25
$-7.4M
$21.9M
Q2 25
$19.4M
Q1 25
$-1.6M
$18.1M
Q4 24
$605.2K
$13.7M
Q3 24
$-6.2M
$-7.9M
Q2 24
$7.7M
Gross Margin
BIOX
BIOX
ORRF
ORRF
Q1 26
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Operating Margin
BIOX
BIOX
ORRF
ORRF
Q1 26
Q4 25
42.3%
Q3 25
9.3%
43.0%
Q2 25
39.6%
Q1 25
1.5%
37.7%
Q4 24
14.5%
27.7%
Q3 24
2.5%
-15.4%
Q2 24
29.5%
Net Margin
BIOX
BIOX
ORRF
ORRF
Q1 26
33.8%
Q4 25
33.1%
Q3 25
-9.6%
34.0%
Q2 25
31.2%
Q1 25
-2.6%
29.9%
Q4 24
0.6%
22.1%
Q3 24
-6.6%
-12.3%
Q2 24
23.3%
EPS (diluted)
BIOX
BIOX
ORRF
ORRF
Q1 26
$1.12
Q4 25
$1.11
Q3 25
$-0.12
$1.13
Q2 25
$1.01
Q1 25
$-0.02
$0.93
Q4 24
$0.00
$0.35
Q3 24
$-0.10
$-0.41
Q2 24
$0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
ORRF
ORRF
Cash + ST InvestmentsLiquidity on hand
$15.5M
$161.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$603.2M
Total Assets
$734.9M
$5.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
ORRF
ORRF
Q1 26
$161.8M
Q4 25
Q3 25
$15.5M
Q2 25
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
Stockholders' Equity
BIOX
BIOX
ORRF
ORRF
Q1 26
$603.2M
Q4 25
$591.5M
Q3 25
$288.3M
$571.9M
Q2 25
$548.4M
Q1 25
$345.0M
$532.9M
Q4 24
$346.3M
$516.7M
Q3 24
$346.0M
$516.2M
Q2 24
$278.4M
Total Assets
BIOX
BIOX
ORRF
ORRF
Q1 26
$5.6B
Q4 25
$5.5B
Q3 25
$734.9M
$5.5B
Q2 25
$5.4B
Q1 25
$798.2M
$5.4B
Q4 24
$835.2M
$5.4B
Q3 24
$827.3M
$5.5B
Q2 24
$3.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
ORRF
ORRF
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
ORRF
ORRF
Q1 26
Q4 25
$74.7M
Q3 25
$14.4M
$22.8M
Q2 25
$24.5M
Q1 25
$23.3M
$11.0M
Q4 24
$-5.4M
$35.0M
Q3 24
$5.2M
$7.5M
Q2 24
$6.4M
Free Cash Flow
BIOX
BIOX
ORRF
ORRF
Q1 26
Q4 25
$70.5M
Q3 25
$22.3M
Q2 25
$23.7M
Q1 25
$8.6M
Q4 24
$33.4M
Q3 24
$7.1M
Q2 24
$6.4M
FCF Margin
BIOX
BIOX
ORRF
ORRF
Q1 26
Q4 25
108.6%
Q3 25
34.7%
Q2 25
37.9%
Q1 25
14.3%
Q4 24
54.0%
Q3 24
11.1%
Q2 24
19.2%
Capex Intensity
BIOX
BIOX
ORRF
ORRF
Q1 26
Q4 25
6.5%
Q3 25
0.8%
Q2 25
1.3%
Q1 25
3.8%
Q4 24
2.6%
Q3 24
0.6%
Q2 24
0.1%
Cash Conversion
BIOX
BIOX
ORRF
ORRF
Q1 26
Q4 25
3.48×
Q3 25
1.04×
Q2 25
1.26×
Q1 25
0.61×
Q4 24
-8.85×
2.55×
Q3 24
Q2 24
0.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

ORRF
ORRF

Net Interest Income$49.0M76%
Noninterest Income$15.6M24%

Related Comparisons